Classificação em ações
#14023
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to... Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Valor de mercado
$442.29M
Negociar Q32 Bio Inc. (QTTB)
Preço QTTB com a capitalização de mercado de B
Capitalização de mercado de Q32 Bio Inc.(QTTB)
Valor de mercado: $442.29M
Em August 2026, Q32 Bio Inc. tem uma capitalização de mercado de $442.29M. Isso faz com que Q32 Bio Inc. seja a 14023rd empresa mais valiosa do mundo em termos de capitalização de mercado, de acordo com os nossos dados. A capitalização de mercado, também chamada de market cap, é o valor total de mercado das ações em circulação de uma empresa de capital aberto e é amplamente utilizada para medir o valor de uma empresa.
Histórico de capitalização de mercado de Q32 Bio Inc. de 2018 a 2026
QTTB comparado com o topo de 5 mais populares stocks
| Preço para QTTB |
|
Ativo B |
Capitalização de mercado de B |
Resultados |
|
|
|
|
$5.327T
|
+1,204,260.77%
|
|
|
|
|
$4.645T
|
+1,050,080.81%
|
|
|
|
|
$4.070T
|
+920,163.32%
|
|
|
|
|
$3.785T
|
+855,572.62%
|
|
|
|
|
$2.790T
|
+630,731.31%
|
